Beijing Business News (Reporter Ding Ning) On the evening of May 26,crashteamracingpcsteam, Baili Tianheng (688506) issued an announcement sayingcrashteamracingpcsteamThe company's independently developed innovative biopharmaceutical injection BL-M07D1 (HER2-ADC) single agent for locally advanced or metastatic HER2-positive breast cancer has recently completed the enrollment of the first subject.
The announcement shows that BL-M07D1 is an ADC drug targeting HER2, and its indications are solid tumors such as breast cancer, gastric cancer, non-small cell lung cancer, gynecological tumors, and urinary system tumors.
